Reviva Pharmaceuticals Holdings, Inc. (RVPH) 株式分析

企業概要

Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical entity engaged in the discovery, development, and commercialization of next-generation therapeutics designed to address unmet medical needs. The company specifically focuses on therapeutic areas including the central nervous system, respiratory conditions, inflammatory diseases, and cardiometabolic disorders. This enterprise operates within the Healthcare sector and functions as a Biotechnology company, positioning it within the specialized ecosystem of medical innovation and drug development. As of the latest data, the company maintains a market capitalization of $10.12M and employs a workforce of 14 individuals, with annual revenue data not available in the current reporting period. The relatively small market cap of $10.12M combined with the absence of reported revenue indicates that the company is likely in an early-stage development phase where value is derived from pipeline potential rather than established commercial sales. This scale suggests a high-risk, high-reward profile typical of small-cap biotechnology firms that prioritize R&D investment over immediate profitability.

財務健全性

The reported net income for the trailing twelve months stands at $-19,864,902, while revenue and EBITDA figures are not available in the current dataset. The significant disparity between the reported net loss and the absence of revenue data reveals a cost structure heavily weighted toward research and development expenses rather than cost of goods sold. The company reports a free cash flow of $-17,137,860, indicating a substantial cash outflow that reflects intensive operational spending required to advance its therapeutic pipeline. Despite this cash burn, the company holds $14.44M in cash reserves, which provides a buffer to fund ongoing operations and development activities without immediate external financing. The analysis of margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, levels that are characteristic of early-stage biotechnology companies before product commercialization or at the point of significant operational losses. The balance sheet presents a mix of liquidity and leverage, with total cash of $14.44M compared against total debt of $406,875, resulting in a debt-to-equity ratio of 4.71. While the debt-to-equity ratio of 4.71 suggests a leveraged position, the absolute debt level is low relative to cash holdings, yet the high ratio indicates significant reliance on equity financing. The current ratio is recorded at 2.08, a figure that suggests the company maintains adequate short-term liquidity to cover its current liabilities with its current assets. Return on Equity is reported at -420.0% and Return on Assets at -80.3%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common phenomenon during the pre-revenue stages of biopharmaceutical development.

バリュエーション評価

Valuation metrics for Reviva Pharmaceuticals Holdings, Inc. present a complex picture due to the lack of profitability, with the P/E Ratio (TTM) listed as N/A and the Forward P/E at -0.96. The negative forward P/E of -0.96 implies that the market is pricing in future earnings that are still negative or that the stock is valued based on non-earnings multiples. The price-to-book ratio stands at 0.54, indicating that the market is valuing the company at a discount to its book value, which often occurs in biotechnology firms where assets like intellectual property are not fully reflected on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both listed as N/A, suggesting that traditional revenue-based or earnings-based valuation models are not applicable given the company's financial structure. The stock has exhibited significant volatility, trading between a 52-week low of $0.59 and a 52-week high of $23.20. Without a specific current price provided in the source facts to calculate the exact percentage difference, the range itself highlights the extreme price swings typical of small-cap biotech stocks. The beta value is 0.64, which indicates that the stock's price volatility is lower than the broader market benchmark, suggesting it may be less sensitive to general market movements despite its inherent sector risks.

Growth & Income

Revenue growth and earnings growth rates for the year-over-year period are both listed as N/A, meaning historical growth trajectories cannot be quantified from the current data. In the absence of reported revenue and earnings growth, it is impossible to determine if earnings are growing faster or slower than revenue, as both metrics are currently unavailable for calculation. As a non-dividend payer, Reviva Pharmaceuticals Holdings, Inc. has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all available cash to reinvest into its research and development pipeline rather than distributing income to shareholders. This reinvestment strategy is essential for biotechnology companies to advance their clinical trials and secure regulatory approvals for new therapeutics. The overall growth and income profile is characterized by a reliance on capital markets for funding rather than organic revenue growth or dividend income, reflecting the capital-intensive nature of developing next-generation therapeutics for central nervous system and cardiometabolic diseases.